title: Aspirin dose and six-month outcome after an acute coronary syndrome.
abstract: OBJECTIVE
  This study was designed to compare the efficacy of low and intermediate aspirin doses in acute coronary syndromes.
  
  
  BACKGROUND
  Little is known of the comparative efficacy of low and intermediate aspirin doses in this setting.
  
  
  METHODS
  We compared six-month death, myocardial infarction (MI), and stroke in patients with unstable angina or acute MI discharged while receiving low (<150 mg) or intermediate (> or =150 mg) aspirin therapy in the GUSTO IIb and PURSUIT trials (n = 20,521). We used multivariable analysis and performed a propensity analysis in order to adjust for baseline imbalances between the groups.
  
  
  RESULTS
  Aspirin doses <150 mg were prescribed to 29.9% (6,128) of patients. By six months, 6.4% of the patients (1,310 of 20,521) had a primary event, 6.2% of the patients receiving <150 mg and 6.6% of the patients receiving aspirin doses > or =150 mg (hazard ratio [HR] 1.06 [95% confidence interval (CI) 0.94 to 1.19], p = 0.35). After adjusting for baseline imbalances and the propensity score for discharge aspirin dose, there was no effect of aspirin dose on the composite end point at six months (HR 0.92 [95% CI 0.79 to 1.07], p = 0.28). However, the higher aspirin dose was associated with a reduction in six-month MI (HR 0.79 [95% CI 0.64 to 0.98], p = 0.03). The outcome was similar when patients were matched on the basis of the propensity score for aspirin dose (HR for death/MI/stroke 0.94 [95% CI 0.80 to 1.12], p = 0.51), although stroke occurred significantly more frequently among patients receiving the higher aspirin dose (HR 1.74 [95% CI 1.01 to 3.02] p = 0.05) and the effect on MI was no longer apparent.
  
  
  CONCLUSIONS
  Although these data are non-randomized, they suggest that the aspirin dose upon discharge may influence the clinical course after unstable angina or acute MI.
authors.affiliation: St. Vincents University Hospital, Dublin, Ireland.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Quinn
authors.forename: Herbert D
authors.initials: HD
authors.lastname: Aronow
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: Shelly
authors.initials: S
authors.lastname: Sapp
authors.forename: Neal S
authors.initials: NS
authors.lastname: Kleiman
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
authors.forename: David F
authors.initials: DF
authors.lastname: Kong
authors.forename: David E
authors.initials: DE
authors.lastname: Kandzari
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007494:Ireland; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000401:mortality / Q000517:prevention & control; D016896:Treatment Outcome; D014481:United States
chemical_list: D000925:Anticoagulants; D001241:Aspirin